Spike Protein News and Research

RSS

ACE2 binding causes dissociation of trimeric SARS-CoV-2 spike, may be used to inhibit further infection

A recent study published on the preprint server bioRxiv in October 2020 shows that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binding to the human host receptor could cause the typical trimeric spike protein to come apart, forming a stable monomer instead with the receptor.

14 Oct 2020

Study shows SARS-CoV-2 antibodies offer lasting immunity

One of the most significant questions about the novel coronavirus is whether people who are infected are immune from reinfection and, if so, for how long.

14 Oct 2020

SARS-CoV-2 spike protein triggers cell signaling pathways in lung vascular cells

A new study published on the preprint server bioRxiv in October 2020 shows that vascular cells in the lung tissue begin to secrete signaling growth factors when exposed to just the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), without the rest of the viral components.

14 Oct 2020

SARS-CoV-2 infection of carotid arteries may explain vascular involvement in COVID-19

A new study published on the preprint server bioRxiv in October 2020 shows that the virus causing COVID-19, namely, SARS-CoV-2, produces replicative infection in the carotid arteries and affects the vascular responses. This could have a profound bearing on the understanding of the disease and its clinical treatment.

14 Oct 2020

New clinical trial to test safety and efficacy of antibody cocktail against COVID-19

In a new clinical trial, UC Davis Health will test the effectiveness and safety of REGN-COV2, the monoclonal antibody cocktail, in preventing COVID-19 in adults living with infected patients.

14 Oct 2020

How SARS-CoV-2's spike protein highjacks the host cell trafficking machinery

Researchers at The Medical Research Council Laboratory of Molecular Biology have conducted a study showing how the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein interacts with host cell factors in ways that promote the formation of syncytia.

13 Oct 2020

Study offers a better understanding of protective antibodies induced by coronavirus

As vaccine trials progress and public health officials brace for a rise in COVID-19 cases, understanding how the body defends itself from SARS-CoV-2 infection is essential.

13 Oct 2020

COVID-19 vaccine candidate shows potent immune response

A COVID-19 vaccine candidate that underwent extensive preclinical testing at the University of Alabama at Birmingham this spring and summer shows potent preclinical immune responses -; including several that distinguish it from other COVID-19 vaccine approaches -; according to a preprint deposited in the BioRxiv repository this week.

13 Oct 2020

Integrin b3 and ACE2 linked by short linear motifs enabling endocytosis and autophagy of SARS-CoV-2

A new study by Uppsala University researchers published on the preprint server bioRxiv in October 2020 shows possible links between the angiotensin-converting enzyme 2 (ACE2) host cell receptors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the entry of viral particles into the cell via endocytosis and autophagy.

12 Oct 2020

Sub-second heat inactivation of coronavirus

Three coronaviruses (CoVs) have caused global outbreaks within the past 20 years, and with the COVID19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still ongoing, methods that can rapidly inactivate these viruses can play critical roles in ensuring public safety and safeguarding personal health.

12 Oct 2020

Nasal spray COVID-19 vaccine shows promising results in mice

With promising vaccines comes a new candidate that has shown potent pre-clinical immune responses. The vaccine, developed by scientists at the University of Alabama at Birmingham (UAB), induced a potent T-cell response at the mucus layer of the lungs, including killer CD8+ T-cells, which can recognize and kill virally infected cells.

12 Oct 2020

COVID-19 survivors may have protective antibodies for 4 months

The study, published in the journal Science Immunology, highlights the body's immune response against COVID-19. Also, it offers hope that people who are infected with the SARS-CoV-2 virus will develop lasting protection against reinfection.

11 Oct 2020

Temporal predictors of SARS-CoV-2 antibodies

Researchers in a recent paper published as a preprint on the preprint medRxiv, study the clinical factors, the laboratory assays to streamline plasma donor selection, and the durability of nAb responses in adults.

11 Oct 2020

New study reports on extremely potent human monoclonal antibodies for SARS-CoV-2

Researchers have recovered and identified the various types of neutralizing antibodies for SARS-CoV-2 from convalescent COVID-19 patients. Of these, they identified three that are extremely potent and could be used to develop treatment therapies.

11 Oct 2020

Vaccines likely to be effective against SARS-CoV-2 D614G mutation

The emergence of the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutation D614G has raised many questions, including whether it will cause the virus to become resistant to the vaccines produced against earlier versions of the virus. A new study published in the journal npj Vaccines in October 2020 shows that this may be an unfounded fear.

11 Oct 2020

Rapid and sensitive detection of SARS-CoV-2 with functionalized magnetic nanoparticles

A recent study published on the preprint server arXiv in October 2020 shows the potential for using functionalized magnetic nanoparticles to detect the presence of the virus in a sample.

11 Oct 2020

Exciting findings on CD8 T cell response in recovered COVID patients

An international team of scientists has identified novel T cell-recognized epitopes spanning different proteins of severe acute respiratory syndrome coronavirus 2 in COVID-19 recovered patients. The scientists have also revealed phenotypical characteristics of the T cell population.

11 Oct 2020

Serum antibodies from SARS-CoV patients effectively neutralized SARS-CoV-2 in cultured cells

Antibodies in serum samples collected from patients infected with SARS-CoV during the 2003 outbreak effectively neutralized SARS-CoV-2 infection in cultured cells, according to a new study.

9 Oct 2020

Long-lasting antibodies detected in blood and saliva of COVID-19 patients

Two separate studies have documented the persistence of antibodies that target SARS-CoV-2 in hundreds of patients with COVID-19 at least 3 months after symptom onset.

9 Oct 2020

Mount Sinai to receive more than $7.3 million as part of NCI's new Serological Sciences Network

Researchers from the Icahn School of Medicine at Mount Sinai will receive more than $7.3 million from the National Cancer Institute as part of the NCI's new Serological Sciences Network (SeroNet), one of the largest coordinated national efforts to study immunology and SARS-CoV-2, the virus that causes COVID-19.

8 Oct 2020

Spike Protein News and Research

ACE2 binding causes dissociation of trimeric SARS-CoV-2 spike, may be used to inhibit further infection

Study shows SARS-CoV-2 antibodies offer lasting immunity

SARS-CoV-2 spike protein triggers cell signaling pathways in lung vascular cells

SARS-CoV-2 infection of carotid arteries may explain vascular involvement in COVID-19

New clinical trial to test safety and efficacy of antibody cocktail against COVID-19

How SARS-CoV-2's spike protein highjacks the host cell trafficking machinery

Study offers a better understanding of protective antibodies induced by coronavirus

COVID-19 vaccine candidate shows potent immune response

Integrin b3 and ACE2 linked by short linear motifs enabling endocytosis and autophagy of SARS-CoV-2

Sub-second heat inactivation of coronavirus

Nasal spray COVID-19 vaccine shows promising results in mice

COVID-19 survivors may have protective antibodies for 4 months

Temporal predictors of SARS-CoV-2 antibodies

New study reports on extremely potent human monoclonal antibodies for SARS-CoV-2

Vaccines likely to be effective against SARS-CoV-2 D614G mutation

Rapid and sensitive detection of SARS-CoV-2 with functionalized magnetic nanoparticles

Exciting findings on CD8 T cell response in recovered COVID patients

Serum antibodies from SARS-CoV patients effectively neutralized SARS-CoV-2 in cultured cells

Long-lasting antibodies detected in blood and saliva of COVID-19 patients

Mount Sinai to receive more than $7.3 million as part of NCI's new Serological Sciences Network

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News